Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?
Evangelista L, Cervino AR, Ghiotto C, Saibene T, Michieletto S, Fernando B, Orvieto E, Guarneri V, Conte P. Evangelista L, et al. Among authors: michieletto s. Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1648-1655. doi: 10.1007/s00259-015-3088-4. Epub 2015 May 31. Eur J Nucl Med Mol Imaging. 2015. PMID: 26025244
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
Dieci MV, Guarneri V, Giarratano T, Mion M, Tortora G, De Rossi C, Gori S, Oliani C, Merlini L, Pasini F, Bonciarelli G, Griguolo G, Orvieto E, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte P. Dieci MV, et al. Among authors: michieletto s. Oncologist. 2018 Mar;23(3):297-305. doi: 10.1634/theoncologist.2017-0322. Epub 2017 Nov 13. Oncologist. 2018. PMID: 29133514 Free PMC article.
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV, Guarneri V, Zustovich F, Mion M, Morandi P, Bria E, Merlini L, Bullian P, Oliani C, Gori S, Giarratano T, Orvieto E, Griguolo G, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte P; Veneto Oncology Network. Dieci MV, et al. Among authors: michieletto s. Oncologist. 2019 Nov;24(11):1424-1431. doi: 10.1634/theoncologist.2019-0103. Epub 2019 May 31. Oncologist. 2019. PMID: 31152079 Free PMC article.
Solitary biceps muscle metastasis from neuroendocrine breast tumor.
Celotto F, Tropea S, Rastrelli M, Saibene T, Gazzetta G, Dieci MV, Scapinello A, Michieletto S. Celotto F, et al. Among authors: michieletto s. Breast J. 2021 Feb;27(2):185-187. doi: 10.1111/tbj.14139. Epub 2020 Dec 22. Breast J. 2021. PMID: 33350531 No abstract available.
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy.
Dieci MV, Griguolo G, Bottosso M, Tsvetkova V, Giorgi CA, Vernaci G, Michieletto S, Angelini S, Marchet A, Tasca G, Genovesi E, Cumerlato E, Lo Mele M, Conte P, Guarneri V. Dieci MV, et al. Among authors: michieletto s. NPJ Breast Cancer. 2021 Aug 2;7(1):101. doi: 10.1038/s41523-021-00308-7. NPJ Breast Cancer. 2021. PMID: 34341356 Free PMC article.
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F, Dieci MV, Tsvetkova V, Griguolo G, Vernaci G, Menichetti A, Faggioni G, Giarratano T, Mioranza E, Genovesi E, Cumerlato E, Bottosso M, Saibene T, Michieletto S, Lo Mele M, Conte P, Guarneri V. Miglietta F, et al. Among authors: michieletto s. Oncologist. 2020 Sep;25(9):e1355-e1362. doi: 10.1634/theoncologist.2020-0201. Epub 2020 Jul 21. Oncologist. 2020. PMID: 32618068 Free PMC article.
43 results